Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Sell
24
AGIO Quote, Financials, Valuation and Earnings
Last price:
$31.67
Seasonality move
:
9.03%
Day range:
$30.81 - $31.92
52-week range:
$27.14 - $62.58
Dividend yield:
0%
P/E ratio:
2.75x
P/S ratio:
49.25x
P/B ratio:
1.16x
Volume:
640.2K
Avg. volume:
704.1K
1-year change:
6.52%
Market cap:
$1.8B
Revenue:
$36.5M
EPS (TTM):
$11.34
Analysts' Opinion
-
Consensus RatingAgios Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $54.57, Agios Pharmaceuticals has an estimated upside of 74.91% from its current price of $31.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $43.00 representing 100% downside risk from its current price of $31.20.
Fair Value
-
According to the consensus of 6 analysts, Agios Pharmaceuticals has 74.91% upside to fair value with a price target of $54.57 per share.
AGIO vs. S&P 500
-
Over the past 5 trading days, Agios Pharmaceuticals has underperformed the S&P 500 by -4.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Agios Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Agios Pharmaceuticals has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Agios Pharmaceuticals reported revenues of $10.7M.
Earnings Growth
-
Agios Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Agios Pharmaceuticals reported earnings per share of -$1.74.
Enterprise value:
893.9M
EV / Invested capital:
0.58x
Price / LTM sales:
49.25x
EV / EBIT:
--
EV / Revenue:
24.49x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-2.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$32.3M
Return On Assets:
56.01%
Net Income Margin (TTM):
-1165.69%
Return On Equity:
62.58%
Return On Invested Capital:
62.58%
Operating Margin:
-1165.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $14.2M | $26.8M | $36.5M | $7.1M | $10.7M | |
| Gross Profit | $12.5M | $23.9M | $32.3M | $6.5M | $9.5M | |
| Operating Income | -$389M | -$391.5M | -$425.7M | -$106.3M | -$125M | |
| EBITDA | -$380.5M | -$384.9M | -$420.1M | -$104.9M | -$123.7M | |
| Diluted EPS | -$4.24 | -$6.34 | $11.34 | -$1.72 | -$1.74 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $636.7M | $1.1B | $832.8M | $833.8M | $965.6M | |
| Total Assets | $853M | $1.4B | $1.2B | $937.1M | $1.7B | |
| Current Liabilities | $94.4M | $59.8M | $62.6M | $68M | $81.2M | |
| Total Liabilities | $453.5M | $145.8M | $137.9M | $126.1M | $122.2M | |
| Total Equity | $399.5M | $1.3B | $1.1B | $811M | $1.5B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$309.5M | -$296.1M | -$389.8M | -$72.5M | -$133.2M | |
| Cash From Investing | $243.3M | $239.6M | $363.4M | $95.5M | -$49.2M | |
| Cash From Financing | $2.4M | $5.4M | $14.4M | $847K | $4.8M | |
| Free Cash Flow | -$314.4M | -$314.6M | -$391.5M | -$72.7M | -$134.1M | |
AGIO
Sector
Market Cap
$1.8B
$37.4M
Price % of 52-Week High
49.86%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
6.52%
-38.36%
Beta (5-Year)
0.903
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$31.96
200-day SMA
Sell
Level
$42.78
Bollinger Bands (100)
Sell
Level
31.33 - 50.79
Chaikin Money Flow
Buy
Level
25.5M
20-day SMA
Sell
Level
$33.27
Relative Strength Index (RSI14)
Sell
Level
38.49
ADX Line
Sell
Level
14.72
Williams %R
Buy
Level
-88.998
50-day SMA
Sell
Level
$33.52
MACD (12, 26)
Sell
Level
-0.86
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
54.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.9085)
Buy
CA Score
(Annual)
Level (-0.0739)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-15.7215)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Stock Forecast FAQ
In the current month, AGIO has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The AGIO average analyst price target in the past 3 months is $54.57.
-
Where Will Agios Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Agios Pharmaceuticals share price will rise to $54.57 per share over the next 12 months.
-
What Do Analysts Say About Agios Pharmaceuticals?
Analysts are divided on their view about Agios Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Agios Pharmaceuticals is a Sell and believe this share price will drop from its current level to $43.00.
-
What Is Agios Pharmaceuticals's Price Target?
The price target for Agios Pharmaceuticals over the next 1-year time period is forecast to be $54.57 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is AGIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Agios Pharmaceuticals is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of AGIO?
You can purchase shares of Agios Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Agios Pharmaceuticals shares.
-
What Is The Agios Pharmaceuticals Share Price Today?
Agios Pharmaceuticals was last trading at $31.67 per share. This represents the most recent stock quote for Agios Pharmaceuticals. Yesterday, Agios Pharmaceuticals closed at $31.20 per share.
-
How To Buy Agios Pharmaceuticals Stock Online?
In order to purchase Agios Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
52
RGC alert for Mar 19
Regencell Bioscience Holdings [RGC] is down 0.66% over the past day.
Sell
49
SRPT alert for Mar 19
Sarepta Therapeutics [SRPT] is up 8.72% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is up 5.74% over the past day.
